key: cord-0743862-2ka0tmer authors: Bogdanos, Dimitrios P.; Smyk, Daniel S.; Invernizzi, Pietro; Rigopoulou, Eirini I.; Blank, Miri; Sakkas, Lazaros; Pouria, Shideh; Shoenfeld, Yehuda title: Tracing environmental markers of autoimmunity: introducing the infectome date: 2013-04-17 journal: Immunol Res DOI: 10.1007/s12026-013-8399-6 sha: 418bd4c4b37f20dabbb30bb68ccc1dad1d6bf5a2 doc_id: 743862 cord_uid: 2ka0tmer We recently introduced the concept of the infectome as a means of studying all infectious factors which contribute to the development of autoimmune disease. It forms the infectious part of the exposome, which collates all environmental factors contributing to the development of disease and studies the sum total of burden which leads to the loss of adaptive mechanisms in the body. These studies complement genome-wide association studies, which establish the genetic predisposition to disease. The infectome is a component which spans the whole life and may begin at the earliest stages right up to the time when the first symptoms manifest, and may thus contribute to the understanding of the pathogenesis of autoimmunity at the prodromal/asymptomatic stages. We provide practical examples and research tools as to how we can investigate disease-specific infectomes, using laboratory approaches employed from projects studying the “immunome” and “microbiome”. It is envisioned that an understanding of the infectome and the environmental factors that affect it will allow for earlier patient-specific intervention by clinicians, through the possible treatment of infectious agents as well as other compounding factors, and hence slowing or preventing disease development. We recently introduced the concept of the infectome as a means of studying all infections throughout life which contribute to the development/progression of disease [1] , as it is now viewed that the majority of diseases develop as a result of the interaction between genetic and environmental influences [2] [3] [4] . Autoimmune diseases are especially seen to be caused by this interaction [2, 3, 5] . It is now estimated that approximately 5-20 % of North Americans are affected by at least one autoimmune disease [6, 7] . The mosaic of autoimmunity is a concept which reflects the fact that many patients with one autoimmune disease have several concomitant autoimmune diseases at any given time with heterogeneous triggers and aetiological factors [8] [9] [10] [11] [12] [13] [14] [15] . Much attention has been given to genetic research on the path to uncovering the underlying factors of autoimmunity [16] . In addition to molecular signalling pathways [17] , genome-wide association studies (GWAS) have identified numerous gene-disease associations in several autoimmune diseases [3] . The essential number of associated genes needed for the maintenance of autoaggressive responses and the development of clinically overt disease has not been properly delineated [18] . However, environmental factors, possibly occurring even in utero, must be given equal attention in the study of the nature of autoimmune disease [2, 3, 19, 20] . Epidemiological and clinical studies using toxicological, microbiological, biochemical and immunological testing are now being used to identify these diverse environmental factors, which include infectious organisms, xenobiotics, chemical compounds and heavy metals, although the list of materials may be exhaustive [2, [21] [22] [23] [24] . Autoimmune (autoinflammatory) syndrome induced by adjuvants (ASIA) is one example where vaccinations and heavy metals have been implicated as triggers of autoimmunity. Recent news regarding the role of prosthetic metal on metal hip replacements has also shown how immune dysfunction and damage can be caused in distant organs due to the release of metals such as chromium and nickel from such prostheses. Recent findings from the National Institute of Environmental Health Sciences workshop on autoimmunity and environment support these findings and have reported significant evidence linking particular autoimmune disease to specific environmental agents [25, 26] . The exact interaction of these exposures and their interplay with genes that confer susceptibility remains poorly defined. It should also be noted that some common mechanisms may underlie the development of all or most autoimmune diseases, with subsequent exposures differentiating one disease from the other [27] . The concept of an ''exposome'' is being used as a means of collating and measuring the effects of environmental factors, both internal and external. These factors may be responsible for increased susceptibility to a disease, or protection from developing the disease. The internal factors include the balance of the flora in the microbiome, the nutritional status of the individual such as vitamin D levels and balance of essential fatty acids, the state of the antioxidant pathways that protect against the deleterious effects of free radicals generated during infective episodes, as well as factors relating to immune function/balance such as the health of the endocrine axis. This review will emphasise the role of the ''infectome'' as the infectious component of the microbiome/exposome which contributes to the development of autoimmune disease. As the infectome could broadly describe the infectious components of the exposome responsible for the induction of non-autoimmune in addition to autoimmune diseases, we may need to differentiate the ''autoinfectome'' from that not related to autoimmunity. In other words, there may be particular components that are only seen in autoimmune disease, and possibly certain features common to all autoimmune diseases. The exposome represents all exogenous and endogenous environmental exposures which begin preconception and carry on throughout life [28] [29] [30] [31] [32] . The endogenous factors are unique to the exposome as compared to previous epidemiological studies [30] . The study of the exposome addresses both external triggers and endogenous factors directly or indirectly linked to the environment [31, 32]. By-products of inflammation, lipid peroxidation, as well as oxidative stress are examples of endogenous sources [30] . Several of these constituents serve as nucleophiles or electrophiles and are capable of DNA and protein modification [33] , which may also occur due to bacterial infection [34] [35] [36] . It is likely that the collation of these components would be unique to a disease, much like GWAS [33] . Also akin to GWAS, quantification of exposure may be a critical piece of information. It may be clinically useful to look at causes within an individual in terms of exposure, times of exposure, sequence of exposure, time-points of exposure events, as well as other risk factors (genetic, epigenetic and other) that induce or maintain an inflammation state and exposure to various stimuli that provoke further autoaggression. If these exposures could be examined independently, they may help identify the pieces of the jigsaw puzzle that lead to the breakdown of tolerance and the induction of pathological alterations as the result of the autoimmune attack. Components of the exposome may also serve as measurable biomarkers [33] in the blood or body fluids of affected . The complexity and breadth of these components would suggest that breaking them down into multiple components may allow for more in-depth analysis [1] . There is no need to underline how difficult it would be to trace down all these highly heterogenous triggers. Homogenous technology platforms suffer from limitations, as all human biomarker measurements are subject to interand intra-subject variance. The creation of a uniform platform that will incorporate and analyse the obtained data would be a milestone, even in the age of ultra-fast computing. Breaking down the heterogenous and highly diverse components could be a more logical step. Screening for the presence of individual infections is routinely used in a small scale [31] . Medium-scale multi-parametric immunoassays for antibodies of various isotypes specific to bacterial or viral antigens, urine and stool cultures and polymerase chain reaction (PCR) are also used in larger laboratories and provide a wealth of information [31] . The ultimate step would be to go a step further and introduce technological platforms that enable high-scale testing of dozens-if not hundreds-of infectious agents at one time, similar to what has been achieved for genes through GWAS. Other functional tests that are available within the realm of scientific research may be brought into clinical and epidemiological use. Examples of these include functional assays of antioxidant pathways, tests of immune sensitivity designed for environmental factors as opposed to biological antigens, DNA adducts, assessment of methylation status and assessment of cellular membrane structure to name but a few. From exposome-to infectome-induced autoimmunity Infectious and non-infectious agents comprise environmental triggers [5, [42] [43] [44] [45] [46] . Non-infectious triggers are numerous, and some examples from our literature search can be found in Table 1 [42, . An infectious burden in autoimmunity has been documented and the triggers are numerous, including bacteria, viruses, parasites and fungi, with variations on particular organisms being found from one autoimmune disease to the next [5, 76, 77] . Geo-epidemiological, microbiological and immunological data indicate the existence of infectious burdens varying from one autoimmune disease to another. Autoantibody burdens in infected individuals have also been noted, but these individuals have not been followed-up for long and it is not know how many of those could develop autoimmune disease [78] . We define the group of disease-causing or disease-linked infections as the ''infectome''. Alterations in the presence of these organisms or the body's immune response to them would also be noted, such as in the case of treatment with antibiotics [79, 80] or exposure to xenobiotics [81] [82] [83] . Such exposures may alter the disease course or its progression by altering the flora present. In contrast to the hygiene hypothesis which supports a protective role played by infections [84] [85] [86] [87] [88] , work on clinical biomaterial and experimental animal models of autoimmune diseases clearly demonstrates that infectious agents break immunological tolerance to self-antigens and can induce autoimmune disease [5] . Examples include acute rheumatic fever presenting several weeks after infection with Streptococcus pyogenes [89] , Helicobacter pylori and autoimmune gastritis [90] , as well as between Trypanosoma cruzi and Chagas' cardiomyopathy [91] , and Mycoplasma with rheumatoid arthritis [92] . These exposures likely begin as early as the transfer of maternal antibodies via the placenta or via breast milk in the gastrointestinal tract, but it is important to identify which of these exposures contributes to the development of disease. It is also important to highlight differences with the microbiome, which identified all microorganisms in a particular region, but is unable to identify those which cause (or protect from) the development and/or progression of a disease. It is also a measure which occurs at a single time point, and thus, only gives a snapshot of which organisms are present throughout a lifetime. Likewise, environmental factors may influence the development of autoimmunity by infectious agents through several routes. The co-expression of xenobiotics or metals, such as nickel, aluminium or mercury, for example, which are now ubiquitous in our environment and a constant part of the human exposome, may act as adjuvants to the immune system. If this occurs in anatomical positions, such as the oral cavity, which is key to the development of oral tolerance through various dental interventions, it may have vast ramification for the development of immunity and autoimmunity. Likewise, the effects of metals have not been fully studied on the human gut microbiome. Potential damage to the gut microflora has potentially extensive implications for the protective role of these floras against pathogen invasion as well as the interactions of the microflora with the mucosal-associated immune system. Mercury is well known for its immunomodulating effects and is frequently used in experimental models for inducing immune reactions (e.g. mercuric chloride model for vasculitis). It also is known to have immunosuppressive effects, and this in its own right may impair the immune system's response to infections (Fig. 1) . Moreover, induction of autoimmunity by viruses or bacteria is probably done by a ''hit-and-run'' mechanism when the causative agent has been cleared from circulation by the time of diagnosis. Tracking down each individual's exposure to infectious agents as well as anti-microbial immune responses may be important for the establishment of a causative link between infection and autoimmunity. The infectome allows for the analysis of affected tissue not only at the time of overt infection, but also allows for the analysis of humoral and cellular immune responses to that infection, possibly some time after the causative organism has been cleared. Hence, the infectome allows for the ongoing surveillance of infection, response and possible change in clinical course. When done in several individuals over time, a particular disease ''fingerprint'' may be established in relation to triggering infectious agents ( Fig. 2) . It is envisioned that the infectome would be most helpful in autoimmune diseases with long subclinical stages and frequent remission-relapse states such as multiple sclerosis (MS), primary biliary cirrhosis (PBC), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) [93] . Highly specific antibodies appear years before the onset of symptoms in most of these diseases [94] [95] [96] . Reasons underlying relapse-remission in these diseases are unknown, making them ideal candidates for the investigation of the infectome. Systemic lupus erythematosus is often characterised by a prodromal stage of anti-Sm and anti-Ro antibody responses with no clinical signs [97, 98] . Many first-degree relatives of SLE patients also have ANA reactivity, predominantly anti-dsDNA and anti-Ro/SSA antibody reactivity [99] [100] [101] . Published data have suggested that high ANA titre, anti-dsDNA, anti-Ro/SSA and anti-chromatin may be of prognostic relevance for the subsequent development of SLE [99] . It is unknown why some, but not all, individuals go on to develop clinical SLE, with disease flares [21] . Multiple infectious factors have been involved in the pathogenesis of SLE, ranging from EBV and cytomegalovirus (CMV) to parvovirus B19 [43, 97, 98, [100] [101] [102] [103] [104] [105] [106] . In the case of CMV, for example, one study found that all female patients with SLE are infected with CMV compared to 75 % of controls [104] . Another study reported that the pp65 antigen of CMV induces autoantibodies in SLE patients and mice prone to develop autoimmune disease [107] . It must be noted that the transient nature of these viruses may influence the detection rates within individuals. Hence, it is difficult to say whether the virus was present at a particular time frame of the disease. It is possible that SLE and/or SLE flares can develop after infection with specific agents, and the study of the infectome can serve as a model to study the role played by infections in such cases. Firstdegree relatives of SLE patients or other individuals at high risk to develop the disease such as those with autoantibody positivity may be screened at regular follow-ups. SLE patients would also be checked, and alterations of clinical phenotypes may be associated with exposure to particular infectious agents. Comprehensive analysis of the data initiated by the infectome may narrow-down the large list of organisms implicated in disease's development. Multiple sclerosis, a chronic autoimmune neurological syndrome, serves as another prototype autoimmune disease in which the infectome model can be assessed, as it is characterised by periods of relapse and remission [108, 109] . It is likely that several risk factors accumulated over a long period of time are responsible for the development of the disease [110] [111] [112] . The relapsing-remitting form of MS is most common and is characterised by flares that include the worsening of previous/current symptoms and the development of new ones [113] . Flares are followed by complete or partial recovery, with a variable period of duration from one patient to the next, and several patients acquire secondary progressive MS. Primary progressive MS (PPMS) is a form of MS characterised by stable progression of the disease with worsening of the symptomatology over the course of time. Two further forms of the disease are also found: the benign form characterised by minimal or mild progression of disability and full recovery of sporadic sensory episodes [113] , and the Marburg variant of MS, a rapidly progressive disease, which eventually leads to death. It is currently unknown as to why these clinically distinct variants exist within one disease [113] . Pathologically, MS is characterised by inflammatory lesions with areas of demyelination in the CNS, which consist of mononuclear cell infiltrates composed of T and B lymphocytes, plasma cells, macrophages and microglia in the perivascular spaces that develop into plaques [108, 114] . Multiple sclerosis has a strong genetic background, as identical twins are 100 times more likely to develop MS if their co-twin has MS, whereas non-twin siblings are 20 times more likely [115, 116] . Previous studies have demonstrated that the strongest genetic association of MS is describes all environmental factors which we are exposed to in a lifetime, both exogenous and endogenous, infectious and noninfectious. Environmental exposures are basically subdivided into infectious and non-infectious agents. The concept of ''infectome'' that we introduce describes the part of the exposome which refers to the collection of an individual's exposures to infectious agents participating in the pathogenesis of autoimmune disease (''auto-infectome''). The infectome can be considered a part of ''microbiome'', the collection of the microbial products which the human body is exposed to at a given time with HLA-DRB1*1501 [117] , though GWAS studies [109] have also implicated non-HLA immunomodulatory genes, including IL7R, IL12RA, CLEC16 and CD226 [118, 119] . In support of a pivotal role for environmental influences in the development of MS is the fact that MS-related implicated genes have only demonstrated an odds ratio of less than 1.3 and that there is a 30 % concordance for MS twins [108, 109, 120, 121] (Table 2) . Vitamin D appears to be a non-infectious agent that is involved in the induction of MS and other autoimmune diseases [109, [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] . Vitamin D appears to play a role in the modulation of pro-inflammatory pathways and T cell regulation [109] . Increased distance from the equator has been correlated with low vitamin D, and interestingly, MS rates increase as distance from the equator increases [108] . As well, populations with increased dietary vitamin D intake have lower rates of MS [109] . An Australian study found a decreased risk of a first demyelinating event in those with increased sun exposure, who also had increased levels of serum vitamin D [135] . This has also been found in other studies [136] . As well, the effect of month of birth on MS development was more apparent in familial MS groupings, suggesting an influence on prenatal vitamin D levels, as well as an interaction between genes and environment [109] . Smoking has also been associated with MS development [137] . Smoking appears to have an interaction with genetic features (so-called gene-environmental interactions) and in particular with HLA-DRB1*15 and the absence of HLA-A*02, which appears to increase the risk of developing MS [138] . Heavy metals may also play a role in some MS patients [139] . Several bacteria and viruses have been implicated in MS (Table 3) [108, 109, 120, 121, 140, 141] , including EBV [108, 109, 120, 121] and human herpesvirus 6 (HHV6) have been implicated. Interestingly, the relapse-remittance pattern of HHV6 is similar to the clinical phenotype of MS [109] , and HHV6 reservoirs have been demonstrated in serum, CSF [142, 143] and CNS tissues of patients with MS [144, 145] . Molecular mimicry involving myelin basic protein and HHV6 encoded U24 mimics, and T cell cross-reactivity has been documented [146] . Other implicated viruses include coronaviruses, varicella zoster virus, Torque teno virus, retroviruses and JC virus [108, 109, 120, 121] . Reactivity to several viral peptides was found, which has led to the speculation that continual exposure to a variety of viruses can lead to T cell expansion reactive against highly conserved proteins, including self-peptides [147] . In addition to providing answers to the aetiology of autoimmune disease, it is also envisioned that the infectome may also identify the cause of certain disease characteristics, such as variable presentation and progression, disease flares, or relapse-remittance. Primary biliary cirrhosis can also be used as a model disease to investigate the role of the infectome [148] . This is largely based in its relatively common (as far as autoimmune disease go) prevalence, its long preclinical phase with positivity for antimitochondrial antibodies (AMA) that are pathognomonic for the disease, its differing progression among patients, and growing evidence for an involvement of genetic, environmental and infectious pathogenetic factors [149] [150] [151] [152] [153] [154] [155] [156] [157] . Clinical, histopathological and experimental data support that the disease is autoimmune [94, 153, . Infectious agents and xenobiotics mimicking the autoepitopic region of PDC-E2, the major PBC self-target, induce PBC-specific autoantibodies and bile duct destruction. Primary biliary cirrhosis is characterised by a long preclinical phase of AMA positivity with no biochemical evidence of liver disease, which is followed by a period of Borrelia burgdorferi [376] Varicella zoster virus [377] [378] [379] Mycobacterium tuberculosis [380] Human cytomegalovirus [381] Retroviruses [382, 383] Coronavirus [384, 385] Torque teno virus [147] JC virus [386, 387] Rubella virus [388] Parainfluenza virus I [389] Measles virus [390, 391] Mumps virus [392] Several infectious agents have been implicated in the pathogenesis of multiple sclerosis (MS), but few have a strong evidence base. Interestingly, only viruses appear to be strongly linked with the disease, whereas several viruses and bacteria have weak or circumstantial associations. It may be the case that several of the infectious agents with a weak evidence base reflect the lack of investigation into these organisms. As well, it is unclear as to whether any of these infectious agents also play a role in the relapsing-remitting course of the disease. By applying the infectome model, it will likely be easier to define which of the organisms listed below (and likely more) are involved in the development and progression of MS, as well as possibly defining particular subtypes of the disease Etio Pathogenesis of Autoimmunity (2013) 56:220- 240 225 biochemical abnormalities and then clinically overt disease. The disease has a long preclinical phase which may take several years. Most sera from patients with PBC have AMA at diagnosis [95, 169, , which is also predictive of eventual disease development [205] . PBC is also characterised by disease-specific anti-nuclear autoantibodies (ANA) that identify patients with worst disease [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] . Familial PBC has been noted and the risk of developing PBC is high amongst family members of PBC patients [222] [223] [224] [225] [226] [227] [228] . Most patients with PBC also have other extra-hepatic disease, including autoimmune rheumatic diseases, and autoimmune thyroiditis. An interesting feature of PBC is that it does not respond to immunosuppressive treatment, which eliminates the need to consider the effects of immunosuppressive therapy on relapse/remission states, thus making PBC ideal for an infectome study. A ''bottom-up'' approach has been taken in various epidemiological studies examining associated risk factors and has identified several environmental factors [149] [150] [151] [152] [ [153] [154] [155] [156] 229] . This has been associated with animal models [153, [230] [231] [232] [233] [234] .Genetic risks involve HLA [235, 236] , non-HLA [237] [238] [239] [240] [241] [242] [243] and sex-linked genes [244] [245] [246] . It is likely that some genetic factors may influence the potential penetrance of infectious agents. For example, HLA-DRB1*11 and HLA-DRB1*13 have a negative association with PBC. It is of interest that such genes confer protection to hepatotropic viruses, such as hepatitis B and C. This highlights the notion that the infectome and GWAS (and likely all exposome components) cannot be studied in isolation. Various pathogens are linked with PBC including E.coli due to a link with UTI (Table 2 ) [158, 176, 244, . Microbial/self-molecular mimicry has been proposed as a bridge linking infections and autoimmunity [158, 176, 247-251, 255, 265, 266, 270-276] . We have previously outlined how the infectome may be studied [1] . In brief, this would involve several steps, beginning with the determination of HLA class I and II, ideally at birth. This may allow for subgrouping individuals into high-or low-risk groups. Second, urine, oro-nasal swabs, saliva, faecal material and blood (for isolation of plasma, serum and peripheral blood mononuclear cells-PBMCs) would be collected, with once-yearly follow-ups with collection of samples. Meticulous recording of clinical data and collection of samples are needed when antiinfective treatment is applied for incidental/casual infections at the preclinical stages of the disease, as this may affect the final outcome of the underlying processes. All samples would be stored and then analysed for associated infectious agents and non-associated agents using multiplex technology (Table 4 ). This type of regular follow-up and sample collection with analysis would occur throughout the disease, paying close attention to the findings at times of change in clinical course, such as the development of symptoms. It should be kept in mind that several patterns of infection may be seen in individuals with a particular disease characteristic or with a particular concomitant autoimmune disease. For example, a differing pattern of infection may be seen in patients with fast-progressing versus slow-progressing PBC. This of course applies to all autoimmune diseases. Can we learn from the microbiome and immunome projects? As described above, the microbiome and infectome are two distinct, yet complementary entities. The microbiome is region/organ-specific (such as the gut, oral cavity or inguinal crease), where microbial genes are found to be prevalent [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] . It provides a snapshot of the flora of that region in a particular state in time and often reflects what would be termed normal flora by performing metagenomic screens of bacterial populations in these regions. The microbiome is not necessarily limited to normal flora, but may also be applied to a disease-affected body site, such as the gastrointestinal tract in children with irritable bowel syndrome (IBS) [283] . Saulnier and colleagues [283] obtained 71 faecal samples from 22 children with IBS and 22 healthy children aged 7-12 years. Analysis showed an elevated percentage of c-proteobacteria in the gut flora of children with IBS, with Haemophilus parainfluenza being a prominent component [283] . Although similar, the infectome relates only to those organisms [170, 172, 256, 258, 393, 394] Novosphingobium aromaticivorans [172, 393] Mycobacterium gordonae [395] [396] [397] Lactobacillus delbrueckii subsp. bulgaricus [250, 270] Viruses Betaretrovirus [263, 267, 398, 399] This It may be argued that the organisms of the human microbiome do not usually induce antigen-specific systemic humoral and cellular immune responses provoking local or systemic inflammatory response, while others believe that these organisms may not be pathogenic, but create disease through dysbiosis of the gut flora and participate in the induction of autoimmunity. This is a key difference between the microbiome and the infectome as the former appreciates the direct or indirect effect of immune responses against infectious agents as pivotal for the initiation of autoaggression and immune-mediated, self-targeting pathology. For the infectome, monitoring of the microbial/host immunity is as important as the isolation of potentially harmful bacterial products, since the host/ microbe immunological interaction is the likely cause of the self-destruction in the case of non-cytopathic viruses and microbes. It may also be important to measure the degree to which normal flora may play in disease, as in the case of dysbiosis where beneficial bacteria become pathogenic, as with E. coli, clostridia and Klebsiella, for example. Although separate, the infectome and microbiome complement each other in providing a micropathological profile (or profiles) of a particular disease. As well, the microbiome is essential to define the normal flora of a particular region and then collectively the entire body. Recent microbiome studies have been able to provide an idea of what ''normal'' may be in the gut by performing metagenomic screens of bacterial populations in these regions [279] [280] [281] [282] 285] . What is normal in one individual may be abnormal for another and may vary from race to race and from one geographical location to the next. Likewise, studies of the gut flora of neonates over the past few decades have shown that the percentage of prevalent bacteria is changing from one generation to the next. An understanding of the normal flora of a particular region (as established by the exposome) is essential. For example, studying the microbiome of the urinary bladder and vagina may help us understand the role of UTI in PBC [149-152, 287, 288] . Investigation of multiple body sites would likely prove to be useful [266, 289] . Population screening is unlikely in the case of the infectome, from both a practical and financial standpoint. It is more logical to study individuals at high risk to develop autoimmune manifestations. These individuals are usually the family members or individuals with HLAs conferring susceptibility to the disease. In those individuals who are initially asymptomatic, or who are at high risk, ongoing sampling and analysis may shed light as to whether the infections that induce the diseases are different to those that participate in the progression of the disease from early to advanced stages. Infectome profiling/burdens may play a decisive role in rapidly progressive patients or in patients who have frequent relapses. Common patterns may become apparent with particular disease subsets. The easiest samples to obtain from patients include blood, urine or saliva. Analysis may be done by several methods and some of those are already in use. IgM, IgA and IgG antibody infectious serology testing is likely to be the most common method of detecting organisms, but also the most economical and efficient. Multiplex immunoassays such as ELISA and indirect immunofluorescence for the detection of antibodies against infectious agents are relatively inexpensive and provide valid information [290] [291] [292] . Largescale multiplex technologies include protein microarrays and peptidome libraries, which are able to detect antibody responses to several hundred antigens [293] [294] [295] . A large German study used a PCR approach to detect a variety of organisms in archived liver tissues of PBC patients [296] , which has been adopted in several other studies examining the role of mycobacteria in PBC [297] [298] [299] , as well as beta-retroviral material in liver and lymph node tissue from PBC patients [267, 268] . Detection of viral and bacterial genetic material in tissues by a multiparametric approach may also prove to be promising. DNA sequencing technology, and specifically the so-called highthroughput DNA sequencers, can determine hundreds of megabases of DNA sequences per run, allowing for the analysis of a broad range of infectious agents [300] [301] [302] [303] . Massive, parallel sequencing might be the next step of this approach for that it is the most sensitive procedure available and allows for the detection of a multitude of infectious agents at the same time [304] . Although immunohistochemical testing for several microbial agents in tissue samples can be applied [305] , it is likely that tissue-based methods will be applied to the infectome, as they are time consuming, and tissue of the affected organ may not be readily available from all patients. The ''topdown'' approach suggested by other researchers may include the analysis of blood, faecal material, urine or saliva is more plausible and can be used for screening and reflecting [30] . Multiplex PCR is a useful tool for evaluating the presence of microorganisms from a variety of sample types. Other technologies include the use of 16S/ 18S rRNA gene sequencing, which allows for the mass analysis of samples [281, 283] . However, one drawback of this approach in comparison with immune profiles is the risk of missing the right time or site of sampling. Multiple body sites may need sampling. In addition to the affected organ, general or systemic infections should be an indication for sampling and may include urine and stool samples in urinary and gastrointestinal tract infections, respectively, or blood cultures in febrile patients. Latent infections such as Lyme disease or mycoplasma may also be detected, in addition to chronic low-grade infections due to dental treatment. It is becoming more apparent that the oral cavity should be examined for infection in patients with autoimmune disease [306] [307] [308] . Alterations in the flora of the oral mucosa, which may lead to a dysbiosis in the gut microbiome, can also contribute to the pathogenesis of IBD [306] . On the other hand, the increased frequency of dental problems in IBD patients may be due to alterations in oral flora. Helenius et al. [308] indicate that patients with rheumatic conditions had various alterations in salivary flow and composition, and oral health. These findings warrant further investigation into the oral flora of patients with autoimmune conditions. The infectome serves not only to characterise which infections lead to the development/progression of disease, but also provides clinicians an opportunity for early intervention and treatment. This could be achieved through the proper use of antibiotic or antiviral therapy, or supportive treatments to prevent damage through free radical stress, which would ideally be initiated early on in the management of these patients. It is envisioned that this intervention may allow for the slower progression of the disease or possibly the prevention of it in at-risk individuals. Guidelines for such treatment should be agreed upon in larger forums, to ensure best patient care and safety [263, 267, 268, 309] . It is now generally viewed that most diseases, including autoimmune disease, develop from an initial genetic susceptibility followed by several environmental exposures, including infections. GWAS is now characterising the genetic components to disease development, with the exposome serving to characterise all exogenous and endogenous environmental exposures. The complex nature of the exposome may require that it be broken down to several sub-components, such as the infectome, which reflects the characterisation and measurement of all infectious organisms that we are exposed to, and which contribute to the development and progression of disease. This characterisation will likely begin with at-risk individuals (such as family members), with further development as patients develop disease symptoms or the progression of the disease changes. Many of these infectious exposures may be preventable or treatable and therefore represent a modifiable set of risk factors in their own right. On the other hand, it may be possible to modulate risk factors for the progression of disease such as the compounding effect of environmental exposures and the body's intrinsic protective pathways through supportive therapies. Dwyer Infectome: a platform to trace infectious triggers of autoimmunity Mechanisms of disease: environmental factors in the pathogenesis of rheumatic disease Autoimmune diseases: insights from genome-wide association studies Infections and autoimmunity-friends or foes? Epidemiology and estimated population burden of selected autoimmune diseases in the United States gender and autoimmune disease Autoimmunity: from the mosaic to the kaleidoscope The mosaic of autoimmunity The mosaic of autoimmunity. a classical case of inhalation of a polyclonal activating factor in a genetically and hormonally susceptible patient leading to multiple autoimmune diseases Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases-2008 The mosaic of autoimmunity: genetic factors involved in autoimmune diseases-2008 Multiple autoimmune diseases in a young woman: tuberculosis and splenectomy as possible triggering factors? Another example of the ''mosaic'' of autoimmunity The mosaic of autoimmunity: the role of environmental factors Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris Environmental and gene-environment interactions and risk of rheumatoid arthritis The circulatory systemic environment as a modulator of neurogenesis and brain aging. Autoimmun Rev Autoimmune thrombocytopenia in three patients treated with captopril Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis Hemolytic anemia associated with chlorpromazine therapy Letter: coombs-positive haemolytic anaemia provoked by chlorpromazine Chlorpromazine-induced antinuclear factors Immune-mediated drug-induced liver disease Drug-induced lupus Drug-induced autoimmune-like hepatitis The role of environmental estrogens and autoimmunity Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden Defining and analyzing geoepidemiology and human autoimmunity Autoantibodies in nonautoimmune individuals during infections Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes Functions of intestinal microflora in children Zinc competition among the intestinal microbiota Autoimmune syndrome induced by adjuvants (ASIA) in the middle east: morphea following silicone implantation Silicone and scleroderma revisited Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality? The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies Infections may have a protective role in the etiopathogenesis of celiac disease T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients Molecular mimicry between Helicobacter pylori antigens and H ? , K ? -adenosine triphosphatase in human gastric autoimmunity Autoimmunity in Chagas' disease. identification of cardiac myosin-b13 trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient Mycoplasmal lipid-associated membrane proteins and Mycoplasma arthritidis mitogen recognition by serum antibodies from patients with rheumatoid arthritis Are autoimmune diseases predictable? Pathogenesis of primary biliary cirrhosis Primary biliary cirrhosis Development of autoantibodies before the clinical onset of systemic lupus erythematosus The curiously suspicious: a role for Epstein-Barr virus in lupus Epstein-barr virus infection induces lupus autoimmunity Studies of Filipino patients with systemic lupus erythematosus: autoantibody profile of first-degree relatives Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? a preliminary report No serological indications that systemic lupus erythematosus is linked with exposure to human parvovirus B19 Acute parvovirus B19 infection in connection with a flare of Human cytomegalovirus in patients with systemic lupus erythematosus Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure Two-year follow-up study after human parvovirus B19 infection Human cytomegalovirus pp 65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice Infectious causes of multiple sclerosis Environmental triggers of multiple sclerosis The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia Multiple sclerosis in North African migrants to France Multiple sclerosis in the Faroe Islands: i Clinical and epidemiological features Multiple sclerosis Multiple sclerosis-the plaque and its pathogenesis A genetic basis for familial aggregation in multiple sclerosis Canadian collaborative study group Evidence for genetic basis of multiple sclerosis the Canadian collaborative study group Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis Risk alleles for multiple sclerosis identified by a genomewide study The type I diabetes association of the IL2RA locus Infectious causes of multiple sclerosis Multiple sclerosis: the environment and causation Vitamin D and autoimmunity: new aetiological and therapeutic considerations SLE: preliminary results The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease Mycobacterium tuberculosis, autoimmunity, and vitamin D Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? The role of vitamin D in regulating immune responses Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis Vitamin D and autoimmune thyroid diseases The clinical significance of 25OH-Vitamin D status in celiac disease Vitamin D insufficiency in a large MCTD population Vitamin D endocrine system involvement in autoimmune rheumatic diseases Sun exposure and vitamin D are independent risk factors for CNS demyelination Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis Smoking and multiple sclerosis: an updated meta-analysis Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis Diagnosis and treatment of metal-induced side-effects Helminths and multiple sclerosis: will old friends give us new treatments for MS? Can infections protect against autoimmunity? Detection of human herpesvirus 6 variant A in peripheral blood mononuclear cells from multiple sclerosis patients Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter The effect of human herpesvirus-6 on cultured human neural cells: oligodendrocytes and microglia Detection of human herpesviruses 6 and 7 genomic sequences in brain tumours Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity What is new in primary biliary cirrhosis? Dig Dis Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients Risk factors for primary biliary cirrhosis in a cohort of patients from the United States Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations Update on primary biliary cirrhosis Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology Genes and (auto)immunity in primary biliary cirrhosis Primary biliary cirrhosis: family stories Twin studies in autoimmune disease: genetics, gender and environment The causes of primary biliary cirrhosis: convenient and inconvenient truths Primary biliary cirrhosis: lymphocyte subsets and function in a time frame Complement profile in primary biliary cirrhosis Primary biliary cirrhosis and autoimmune rheumatic diseases: prediction and prevention Primary biliary cirrhosis is a multisystem disorder Primary biliary cirrhosis: increasing problem, approaching solution The complement system and primary biliary cirrhosis Primary biliary cirrhosisassociation or overlap with other autoimmune diseases Is it possible to predict and prevent primary biliary cirrhosis? IL-2 receptor alpha deficiency and features of primary biliary cirrhosis Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis Antimitochondrial and other autoantibodies The role of E. coli infection in the pathogenesis of primary biliary cirrhosis Origin of cross-reactive autoimmunity in primary biliary cirrhosis Bacteria and primary biliary cirrhosis Primary biliary cirrhosis: paradigm or paradox for autoimmunity The peculiar autoimmunity of primary biliary cirrhosis HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis Positive markers in AMA-negative PBC Primary biliary cirrhosis Primary biliary cirrhosis Autoimmune liver serology: current diagnostic and clinical challenges Disease-specific autoantibodies in primary biliary cirrhosis New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy Antinuclear autoantibodies in chronic liver diseases Common lupus anti-DNA antibody idiotypes in chronic liver diseases Anti-Rnp antibodies in chronic liver diseases Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases Natural (antiphospholipid-PDH,-DNA) autoantibodies and their physiologic serum inhibitors Isotypic distribution of anti-pyruvate dehydrogenase antibodies in patients with primary biliary cirrhosis and their family members Natural autoantibodies in sera of patients with Gaucher's disease Antipyruvate dehydrogenase autoantibodies in primary biliary cirrhosis Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases Pyruvate dehydrogenase as an antigen to detect antimitochondrial antibodies Detection of antimitochondrial antibodies: characterization by enzyme immunoassay and immunoblotting Primary Sjogren's syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis Natural history of early primary biliary cirrhosis Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis Antimitochondrial antibodies in primary biliary cirrhosis Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis Profile and clinical significance of antinuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Primary biliary cirrhosis and the nuclear pore complex IgM predominance in autoimmune disease: genetics and gender Familial primary biliary cirrhosis Prevalence of familial disease in primary biliary cirrhosis in Italy Familial primary biliary cirrhosis in Hiroshima Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis Are increased individual susceptibility and environmental factors both necessary for the development of primary biliary cirrhosis? Primary biliary cirrhosis in mother and daughter Immunological studies in familial primary biliary cirrhosis. Gastroenterology Potential roles for infectious agents in the pathophysiology of primary biliary cirrhosis: what's new? Curr Infect Dis Rep Animal models of primary biliary cirrhosis Progress in the genetics of primary biliary cirrhosis Etiopathogenesis of primary biliary cirrhosis The unfinished business of primary biliary cirrhosis Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis Primary biliary cirrhosis: one disease with many faces Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving Shared familial aggregation of susceptibility to autoimmune diseases Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients Frequency of monosomy X in women with primary biliary cirrhosis Female predominance and X chromosome defects in autoimmune diseases Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis Primary biliary cirrhosis specific antinuclear antibodies in patients from Spain Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis Autoantibodies in primary biliary cirrhosis: analysis of reactivity against eukaryotic and prokaryotic 2-oxo acid dehydrogenase complexes Anti-Helicobacter pylori antibody responses specific for VacA do not trigger primary biliary cirrhosis-specific antimitochondrial antibodies Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? Molecular mimicry in liver disease Bacteriuria and primary biliary cirrhosis Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis? Natural history of bacteriuria in women with primary biliary cirrhosis and the effect of antimicrobial therapy in symptomatic and asymptomatic groups M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria Genetics of liver disease: immunogenetics and disease pathogenesis No specific association between primary biliary cirrhosis and bacteriuria? Is there a relation between Chlamydia infection and primary biliary cirrhosis? Patients with primary biliary cirrhosis make anti-viral and antimitochondrial antibodies to mouse mammary tumor virus Are transient environmental agents involved in the cause of primary biliary cirrhosis? Evidence from space-time clustering analysis Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis Does a betaretrovirus infection trigger primary biliary cirrhosis? Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis Molecular mimicry and autoimmune disease Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences Unusual suspects in primary biliary cirrhosis Epstein-barr virus as a trigger of autoimmune liver diseases Pathogenesis of autoimmune hepatitis Autoimmune hepatitis Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison Enterotypes of the human gut microbiome Metagenomic analysis of the human distal gut microbiome Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes Human distal gut microbiome A human gut microbial gene catalogue established by metagenomic sequencing Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome The human gut microbiome: are we our enterotypes? A core gut microbiome in obese and lean twins High diversity of the saliva microbiome in batwa pygmies Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside An increased risk of urinary tract infection precedes development of primary biliary cirrhosis Autoimmunity and environment: am I at risk? Discerning trends in multiplex immunoassay technology with potential for resource-limited settings Next revolution in the molecular theranostics of infectious diseases: microfabricated systems for personalized medicine Multiparametric technologies for the diagnosis of syndromic infections Protein microarrays and biomarkers of infectious disease Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes Autoantigen discovery with a synthetic human peptidome Hepatic granulomas: histological and molecular pathological approach to differential diagnosis-a study of 442 cases Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis Are infectious agents involved in primary biliary cirrhosis? A PCR approach Mycobacteria-related to the aetiopathogenesis of primary biliary cirrhosis? Using a pan-viral microarray assay (Virochip) to screen clinical samples for viral pathogens Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity Metagenomic analysis of bacterial infections by means of high-throughput DNA sequencing Metagenomics for the discovery of novel human viruses The sensitivity of massively parallel sequencing for detecting candidate infectious agents associated with human tissue Induced expression of heat-shock protein on biliary epithelium in patients with primary sclerosing cholangitis and primary biliary cirrhosis The role of oral hygiene in inflammatory bowel disease Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis Oral and salivary parameters in patients with rheumatic diseases Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders Alfa and beta estrogen receptors and the biliary tree Estrogen receptors in immunity and autoimmunity Effect of the anti-estrogen, Nafoxidine, on NZB/W autoimmune disease Estrogen exaggerates lupus but suppresses T-celldependent autoimmune disease Estrogen and autoimmune disease Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2 Autoimmune hepatitis Drug-induced immune hemolytic anemia Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction Rifampin-induced hypothyroidism in patients with Hashimoto's thyroiditis Belated diagnosis in three patients with rifampicin-induced immune haemolytic anaemia Drug-induced autoimmune-like hepatitis: a case of chronic course after drug withdrawal author reply 5 Drug-induced autoimmune hepatitis: clinical characteristics and prognosis Minocycline-induced dermatomyositis Minocycline induced lupus and autoimmune hepatitis Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors Minocycline-induced hepatitis with autoimmune features and neutropenia Minocycline-induced autoimmune hepatitis with subsequent cirrhosis Minocycline induced lupus and autoimmune hepatitis Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome Minocycline-induced autoimmune hepatitis Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl Autoimmunity and hepatitis A vaccine in children Neuromuscular disorders associated with Hepatitis B vaccination Hepatitis B-related autoimmune manifestations Vaccination and systemic lupus erythematosus: the bidirectional dilemmas Vaccines, viruses, and voodoo Epidemiology of autoimmune reactions induced by vaccination Vaccine-induced autoimmunity Multiple sclerosis and hepatitis B vaccination Autoimmunity, environmental exposure and vaccination: is there a link? Toxicology Vaccination as an additional player in the mosaic of autoimmunity Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? Bcg and autoimmunity: another two-edged sword Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev Effects of tobacco smoke on immunity, inflammation and autoimmunity New insights into the immunology of chronic obstructive pulmonary disease What can epidemiology tell us about systemic lupus erythematosus? Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Effect of cigarette smoke on autoimmunity in murine and human systemic lupus erythematosus An unusually complicated case of primary Sjogren's syndrome: development of transient ''lupus-type'' autoantibodies following silicone implant rejection Silicone gel breast implants and connective tissue disease-a comprehensive review Multiple autoantibodies in patients with silicone breast implants Where there's smoke there's fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined Rupture of silicone gel breast implants and symptoms of pain and fatigue A comparison of autoantibody production in asymptomatic and symptomatic women with silicone breast implants Silicone and autoimmunity Epstein-Barr virus in pediatric multiple sclerosis Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up The causal cascade to multiple sclerosis: a model for MS pathogenesis Primary infection with the Epstein-Barr virus and risk of multiple sclerosis Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2 A casecontrol study of multiple sclerosis Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain Epstein-Barr virus: exploiting the immune system Multiple sclerosis and Epstein-Barr virus Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis Plaque-associated expression of human herpesvirus 6 in multiple sclerosis Human herpesvirus 6 Lyme borreliosis and multiple sclerosis: any connection? A seroepidemic study Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis Brief presence of varicella-zoster vral DNA in mononuclear cells during relapses of multiple sclerosis Varicellazoster virus in cerebrospinal fluid at relapses of multiple sclerosis Spinal fluid lymphocytes from a subgroup of multiple sclerosis patients respond to mycobacterial antigens Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. the collaborative research group on multiple sclerosis Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients Detection of coronavirus RNA and antigen in multiple sclerosis brain Human coronavirus gene expression in the brains of multiple sclerosis patients Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients Characterization of JC virus DNA amplified from urine of chronic progressive multiple sclerosis patients Viral antibodies in cerebrospinal fluid of multiple sclerosis and control patients: comparison between radioimmunoassay and conventional techniques Fusion of cultured multiple-sclerosis brain cells with indicator cells: presence of nucleocapsids and virions and isolation of parainfluenza-type virus Measles virus nucleotide sequences: detection by hybridization in situ Impaired measles virus-specific cytotoxic T cell responses in multiple sclerosis Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls Infectious agents in the pathogenesis of primary biliary cirrhosis Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis Antibodies to mycobacterial 65-kD heat shock protein crossreact with the main mitochondrial antigens in patients with primary biliary cirrhosis Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis Does a betaretrovirus infection trigger primary biliary cirrhosis? Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models The authors declare that they have no conflict of interest.